Nyala Becky Azangue, Nurse Anesthetist, Certified Registered Medicare: Medicare Enrolled Practice Location: 5126 Hospital Dr Ne, Covington, GA 30014 Phone: 404-428-0608 |
Dexter Cicero Poss, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 5126 Hospital Dr Ne, Covington, GA 30014 Phone: 770-786-7053 |
Kathleen Hurlbut Gangl, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 5126 Hospital Dr Ne, Covington, GA 30014 Phone: 770-478-9877 |
Dadonna M Marshall, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 5126 Hospital Dr Ne, Covington, GA 30014 Phone: 770-478-9877 Fax: 770-478-2908 |
News Archive
Concateno (>Europe's leading drug and alcohol test provider, has been awarded the prestigious Queen's Award for Enterprise (http://www.queensawards.org.uk/business/business.html ) in recognition of its outstanding innovation and commercial performance.
Arno Therapeutics, Inc. announced today that its Phase II clinical study of AR-67 has met pre-defined interim goals for patients with glioblastoma multiforme (GBM) who were not previously treated with Avastin and will continue toward completion.
Medtronic, Inc. announced today that Test B4U Drive, the first-ever, free program for teens with diabetes combining advanced driver skills training with diabetes management education, will be held July 19-21 at The Forum in Los Angeles. In partnership with the Juvenile Diabetes No Limits Foundation, Medtronic will continue the program throughout the summer across the country to teach teens with diabetes that good diabetes management is a key to staying safe behind the wheel.
Cancer-related fatigue is a prevalent and potentially persistent issue among breast cancer survivors, which can prevent them from returning to their previous life well after treatment ends and they are declared free of disease.
Anavex Life Sciences Corp. is pleased to announce that it has raised $1,575,000 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73, the company's lead drug candidate for Alzheimer's disease, to advance other compounds in the Anavex pipeline, and for general corporate purposes.
› Verified 2 days ago